Comparative Pharmacology
Head-to-head clinical analysis: AMINOPHYLLINE DYE FREE versus ELIXICON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOPHYLLINE DYE FREE versus ELIXICON.
AMINOPHYLLINE DYE FREE vs ELIXICON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminophylline is a salt form of theophylline that exerts bronchodilation by inhibiting phosphodiesterase, increasing intracellular cAMP. It also blocks adenosine receptors, stimulates central respiratory drive, and reduces diaphragmatic fatigue.
Theophylline is a xanthine derivative that inhibits phosphodiesterase, leading to increased intracellular cyclic AMP levels. It also acts as a nonselective adenosine receptor antagonist, resulting in bronchodilation and anti-inflammatory effects.
Loading dose: 6 mg/kg IV over 30 minutes (use ideal body weight). Maintenance: 0.5-0.7 mg/kg/hour IV infusion for non-smoking adults; 0.8-1.0 mg/kg/hour for smokers. Oral: 200-400 mg every 6-8 hours (extended-release formulations available).
400 mg orally every 6 hours or 600 mg orally every 8 hours; extended-release: 600-1200 mg orally every 12 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 7-9 hours in healthy adults. In smokers, half-life decreases to 4-5 hours. In patients with hepatic cirrhosis, heart failure, or COPD, half-life may prolong to 20-30 hours.
Terminal elimination half-life: 4-6 hours in adults; 3-4 hours in children; prolonged in hepatic impairment or congestive heart failure. Context: dosing interval adjustment required in these conditions.
Primarily hepatic metabolism (approximately 90%) to 1,3-dimethyluric acid and other metabolites; renal excretion of unchanged drug accounts for about 10-13% of the dose. Less than 1% is excreted via bile or feces.
Renal: 50% unchanged; hepatic metabolism to 3-methylxanthine, theophylline, etc. Biliary/fecal: minimal.
Category C
Category C
Xanthine Bronchodilator
Xanthine Bronchodilator